Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial

Efficacy and Safety of Azithromycin 1.5% Eye Drops for Purulent Bacterial Conjunctivitis in Pediatric Patients

“…During clinical evaluation, the azithromycin treatment was rated as satisfactory/very satisfactory for 96% of children by the investigator and rated as comfortable by 97% of children. The good safety profile of azithromycin 1.5% eye drops was demonstrated by this study as well as by the trachoma study, a study involving 670 children of 1 to 10 years old with active trachoma, 35 ie, in more than 800 children. Azithromycin 1.5% eye drops antibacterial activity, rapidly shown on day 3 and maintained at day 9, is obtained with a number of instillations much lower than tobramycin and has the advantages of a shorter treatment duration and less frequent dosing than all the current available antimicrobial eye drops.…”

Adverse Events after Mass Azithromycin Treatments for Trachoma in Ethiopia

“…[12][13][14] Results of this study are also consistent with those of several reports of mass azithromycin treatment of trachoma, which have reported adverse events in 0-9% of treated persons. [15][16][17][18] Other trachoma studies have reported a higher occurrence of adverse events, although these reports are not directly comparable to this study because of differences in reporting adverse events, and because interviewers used a method in which they asked about specific conditions. 6,19 In our study, we asked an open-ended question, which may have elicited fewer positive responses compared with other methods.…”

“…6,19 In our study, we asked an open-ended question, which may have elicited fewer positive responses compared with other methods. 20 Those reports that have described adverse events after azithromycin treatment for trachoma were conducted in settings in which the entire community did not receive azithromycin [15][16][17][18][19]21 or in which only 1-2 communities were monitored, 17,19 or in which only children 6,16,17,21 or adults 15 were monitored. The current study design is noteworthy for several reasons.…”

New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system

“…It is one of the most common causes of preventable blindness in the world, representing 3.6% of total blindness. Traditional antibiotic strategy has been 1% tetracycline ointment, twice daily for 6 weeks or intermittently for 6 months (Cochereau et al, 2007). The strategy recommended by the WHO is a single oral dose of ATM (20 mg/kg in children or 1 g in adults), which has equal efficacy to several weeks of tetracycline (Bowman et al, 2000).…”